

Industry-sponsored satellite symposium - I

Pfizer

Friday 2 September

08:00-09:00 Hall: Kaldalón

RA-current disease understanding and future aspects

08:00-08:05 Welcome and Introduction

Guðrún Björk Reynisdóttir, MD, PhD, Landspítali, University Hospital, Reykjavík, Iceland (Chairman)

08:05-08:25 Novel Insights into Early Pathogenic Mechanisms in RA

Anca Catrina, MD, PhD, Rheumatology unit, Department of Medicine, Karolinska University Hospital, Solna, Sweden

08:25-08:50 Inflammation and Joint Damage Assessed by Imaging - Importance to the patient

Professor, Mikkel Østergaard MD, PhD, DMSc, COPECARE, Center for Rheumatology and Spine Diseases, Rigshospitalet, Copenhagen, Denmark

08:50-09:00 Q and A

All

Industry-sponsored satellite symposium - II

Celgene

Friday 2 September

08:00-09:00 Hall: Silfurberg B

Apremilast in PsA - Is there a link between guidelines and immunology?

08:00-08:10 Welcome and introduction

*Professor Björn Gudbjörnsson MD PhD (Chair), Center for Rheumatology Research, National University Hospital, Reykjavík, Iceland. Member of GRAPPA**

08:10-08:35 The newly published GRAPPA PsA guidelines - addressing the disease domains

*Dr. Þorvaldur Jón Love MD PhD Department of Rheumatology, University of Iceland, Iceland. Member of GRAPPA**

08:35-09:00 How does Apremilast MoA correlate to the PsA disease domains?

Dr. Peter Schafer PhD, Department of Translational Development, Celgene, USA

Industry-sponsored satellite symposium - III

Janssen

Friday 2 September

12:30-13:30 Hall: Kaldalón

Psoriatic arthritis - a disease with many faces, challenges and new treatment options

Learning objectives:

Describe the importance of the roles of IL-12 and IL-23 in the pathogenesis of PsA
Debate the advantages and limitations of current PsA therapy, clinical outcomes and treatment strategies

Discuss treatment recommendations and potential of future therapies

12:30-12:40 Welcome and Introduction by Lars Erik Kristensen

Lars Erik Kristensen

12:40-13:00 IL-23 and its involvement in the pathogenesis of PsA and inflammatory disease

Bruce Kirkham

13:00-13:15 Important clinical outcomes measures in PsA

Tore K Kvien

13:15-13:30 Panel discussion with Tore K Kvien, Bruce Kirkham and Lars Erik Kristensen

Chaired by Lars Erik Kristensen

Industry-sponsored satellite symposium - IV

Eli Lilly

Friday 2 September

17:00-18:00 Hall: Kaldalón

Discussing unmet needs in rheumatoid arthritis: new pathways, new implications

Objectives:

- Explain and support the rationale behind emerging anti-rheumatic agents with novel MOAs by discussing state of the art and unmet needs in RA management.
- Ground the therapeutic potential of JAK inhibition in state-of-the-art evidence on the role of JAK/STAT-mediated signal transduction both in homeostasis and as mediators of dysregulated cytokine signaling in RA.

17:00-17:30 Managing rheumatoid arthritis today: Do we need to do more?

Tore K. Kvien

Rheumatoid arthritis is a heterogeneous complex syndrome with impact well beyond the joints. The last few decades tremendous developments within rheumatoid arthritis treatment have greatly improved the management of patients. Despite the recent advances there are still rheumatoid arthritis patients that do not achieve remission.

17:30-18:00 Pathophysiology of rheumatoid arthritis: Key mechanisms and rationale for emerging therapeutic targets

Peter C. Taylor

While anti cytokine therapies for moderate to severe rheumatoid arthritis have transformed the treatment paradigm, there still remain significant limiting factors. Can targeting intracellular signal transduction pathways be a valuable addition to treatment options?

Industry-sponsored satellite symposium - V

Novartis

Saturday 3 September

12:45-13:45 Hall: Kaldalón

How can IL-17A inhibition meet current unmet needs in AS?

- | | |
|--------|---|
| 15 min | Introduction to unmet needs and current treatment paradigm in AS
<i>Guro Løvik Goll, Diakonhjemmet Hospital, Oslo</i> |
| 35 min | Ankylosing spondylitis: New treatment opportunities. The role of IL-17A and presentation of clinical data
<i>Bruce Kirkham, Guy's and St. Thomas' Hospital, London</i> |
| 10 min | Discussion |